Fainting freshmen and sinking sophomores: Cardiovascular issues of the adolescent

Current Opinion in Pediatrics

Volumn 16, Issue 4, 2004, Pages 350-356

  DiVasta, Amy Desrochers ^a   Alexander, Mark E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COCAINE; ERYTHROPOIETIN; FLUDROCORTISONE; ION CHANNEL; METHAMPHETAMINE; METHYLPHENIDATE; METOPROLOL; MIDODRINE; MINERALOCORTICOID; SEROTONIN UPTAKE INHIBITOR;

ANAMNESIS; ATHLETE; AWARENESS; CARDIOVASCULAR DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COMPETITION; CONGENITAL HEART DISEASE; DEPRESSION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EATING DISORDER; EDEMA; EDUCATION; ELECTROCARDIOGRAM; EVALUATION; EXERCISE; FATIGUE; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPOKALEMIA; LONG QT SYNDROME; MANAGEMENT; MEDICAL SPECIALIST; PARESTHESIA; PATIENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; REFLEX; REVIEW; SCREENING; SIDE EFFECT; SUBSTANCE ABUSE; SYNCOPE; TACHYCARDIA; URINE RETENTION;

ADOLESCENT; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; EATING DISORDERS; HEART; HEART DEFECTS, CONGENITAL; HUMANS; LONG QT SYNDROME; SYNCOPE; SYNCOPE, VASOVAGAL;

EID: 3442902208     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000133079.40007.62     Document Type: Review

References (58)

1. Willis J: Syncope. Pediatr Rev 2000, 21:201-203. [Quiz, 204.]
2. McLeod KA: Syncope in childhood. Arch Dis Child 2003, 88:350-353. This recent review provides readers with a general overview of syncope, focusing on etiology, diagnosis, and treatment modalities.
3. Driscoll DJ, Edwards WD: Sudden unexpected death in children and adolescents. J Am Coll Cardiol 1985, 5:118B-121B.
4. Neuspiel DR, Kuller LH: Sudden and unexpected natural death in childhood and adolescence. JAMA 1985, 254:1321-1325.
5. Walsh CA: Syncope and sudden death in the adolescent. Adolesc Med 2001, 12:105-132.
6. Lewis DA, Dhala A: Syncope in the pediatric patient. The cardiologist's perspective. Pediatr Clin North Am 1999, 46:205-219.
7. Stewart JM: Orthostatic intolerance in pediatrics. J Pediatr 2002, 140:404-411.
8. Ritter S, Tani LY, Etheridge SP, et al.: What is the yield of screening echocardiography in pediatric syncope? Pediatrics 2000, 105:E58.
9. Stewart JM: Transient Orthostatic hypotension is common in adolescents. J Pediatr 2002, 140:418-424.
10. Boehm KE, Morris EJ, Kip KT, et al.: Diagnosis and management of neurally mediated syncope and related conditions in adolescents. J Adolesc Health 2001, 28:2-9.
11. Kapoor WN, Smith MA, Miller NL: Upright tilt testing in evaluating syncope: a comprehensive literature review. Am J Med 1994, 97:78-88.
12. Fitchet A, Stirling M, Burnett G, et al.: Holter monitoring vs tilt testing in the investigation of suspected vasovagal syncope. Pacing Clin Electrophysiol 2003, 26:1523-1527. This study compares the value of Holter monitoring versus tilt testing for diagnosis of a syncopal episode. The authors conclude that Holter monitoring is not indicated in routine evaluation.
13. Saarel EV, Stefanelli CB, Fischbach PS, et al.: Transtelephonic electrocardiographic monitors for evaluation of children and adolescents with suspected arrhythmias. Pediatrics 2004, 113:248-251. This discussion focuses primarily on the ability of transtelephonic monitors to capture pathologic arrhythmia, and outlines the patient populations who may benefit from this relatively simple technology.
14. Rossano J, Bloemers B, Sreeram N, et al.: Efficacy of implantable loop recorders in establishing symptom-rhythm correlation in young patients with syncope and palpitations. Pediatrics 2003, 112:e228-e233. The authors demonstrate that the implantable loop recorder is highly effective when making a diagnosis of arrhythmia is critical, and symptoms are infrequent, short-lived, and frightening.
15. Mtinangi BL, Hainsworth R: Increased orthostatic tolerance following moderate exercise training in patients with unexplained syncope. Heart 1998, 80:596-600.
16. Cadman CS: Medical therapy of neurocardiogenic syncope. Cardiol Clin 2001, 19:203-213.
17. Salim MA, DiSessa TG: Serum electrolytes in children with neurocardiogenic syncope treated with fludrocortisone and salt. Am J Cardiol 1996, 78:228-229.
18. Madrid AH, Ortega J, Rebollo JG, et al.: Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 2001, 37:554-559.
19. Scott WA, Pongiglione G, Bromberg Bl, et al: Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995, 76:400-402.
20. Low PA, Gilden JL, Freeman R, et al.: Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997, 277:1046-1051.
21. Benditt DL, Fahy GJ, Lurie KG, et al.: Pharmacotherapy of neurally mediated syncope. Circulation 1999, 100:1242-1248.
22. Kawakami K, Abe H, Harayama N, et al.: Successful treatment of severe orthostatic hypotension with erythropoietin. Pacing Clin Electrophysiol 2003, 26:105-107.
23. Wren C, O'Sullivan JJ, Wright C: Sudden death in children and adolescents. Heart 2000, 83:410-413.
24. Soteriades ES, Evans JC, Larson MG, et al.: Incidence and prognosis of syncope. N Engl J Med 2002, 347:878-885.
25. Wren C: Sudden death in children and adolescents. Heart 2002, 88:426-431.
26. Nishimura RA, Holmes DR Jr: Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004, 350:1320-1327. This is an excellent, up-to-date review of hypertrophic cardiomyopathy.
27. Friedman MJ, Mull CC, Sharieff GQ, et al.: Prolonged QT syndrome in children: an uncommon but potentially fatal entity. J Emerg Med 2003, 24:173-179.
28. Moss AJ: Long QT Syndrome. JAMA 2003, 289:2041-2044. This article provides an excellent overview of LQTS, including recent advances in the genetics of the disorder and full diagnostic criteria.
29. Moss AJ, Zareba W, Hall WJ, et al.: Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000, 101:616-623.
30. The University of Arizona Center for Education and Research on Therapeutics: QT Drugs Lists. Available at http://www.torsades.org/medical-pros/ drug-lists/drug-lists.htm#. This is a comprehensive and frequently updated list of drugs affecting the QT interval, and is appropriate for both patients and providers.
31. Behr E, Wood DA, Wright M, et al.: Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. Lancet 2003, 362:1457-1459.
32. Brugada J, Brugada R, Brugada P: Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003, 108:3092-3096.
33. Plunkett A, Hulse JA, Mishra B, et al.: Variable presentation of Brugada syndrome: lessons from three generations with syncope. BMJ 2003, 326:1078-1079.
34. Gaita F, Giustetto C, Bianchi F, et al.: Short QT syndrome: a familial cause of sudden death. Circulation 2003, 108:965-970.
35. Napolitano C, Priori SG: Genetics of ventricular tachycardia. Curr Opin Cardiol 2002, 17:222-228.
36. Maron BJ: Sudden death in young athletes. N Engl J Med 2003, 349:1064-1075. This is an update of Maron's classic cohort of sudden death in the athlete. Both recognition of the underlying substrates for sudden death and the limitations in disease screening are addressed.
37. Berul CI: Cardiac evaluation of the young athlete. Pediatr Ann 2000, 29:162-165.
38. Link MS: Mechanically induced sudden death in chest wall impact (commotio cordis). Prog Biophys Mol Biol 2003, 82:175-186.
39. Corrado D, Basso C, Rizzoli G, et al.: Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003, 42:1959-1963. This provocative article reviews the Veneto experience in Italy, and suggests that sports activity is associated with an increased risk of sudden death, both in males and females. The authors conclude that sports activity, per se, was not a cause of the enhanced mortality, but triggered sudden death in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.
40. Garza MM: An AED in every school: the next step for public access defibrillation. Jems 2003, 28:22-23.
41. Hazinski MF, Markenson D, Neish S, et al.: Response to cardiac arrest and selected life-threatening medical emergencies: the medical emergency response plan for schools. A statement for healthcare providers, policymakers, school administrators, and community leaders. Pediatrics 2004, 113:155-168.
42. Haller CA, Benowitz NL: Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000, 343:1833-1838.
43. Center for Disease Control and Prevention. Surveillance Summaries, June 28, 2002. MMWR Morb Mortal Wkly Rep 2002, 51:. Also available at www. cdc.gov/mmwr.
44. Ghuran A, van Der Wieken LR, Nolan J: Cardiovascular complications of recreational drugs. BMJ 2001, 323:464-466.
45. Singh D, Artman M: Toxic exposures. Adolesc Med 2001, 12:133-145.
46. Kurtzman TL, Otsuka KN, Wahl RA: Inhalant abuse by adolescents. J Adolesc Health 2001, 28:170-180.
47. Lorenc JD: Inhalant abuse in the pediatric population: a persistent challenge. Curr Opin Pediatr 2003, 15:204-209. This article reviews the most recent epidemiologic data on inhalant abuse, summarizes the types of substances used and their mechanism of actions, and discusses clinical toxicity and medical management.
48. McLeod KA: Dizziness and syncope in adolescence. Heart 2001, 86:350-354.
49. Stewart JM, Gewitz MH, Weldon A, et al.: Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics 1999, 103:116-121.
50. Tanaka H, Matsushima R, Tamai H, et al.: Impaired postural cerebral hemodynamics in young patients with chronic fatigue with and without orthostatic intolerance. J Pediatr 2002, 140:412-417.
51. Rowe PC, Calkins H, DeBusk K, et al.: Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 2001, 285:52-59.
52. Walker WT, Temple IK, Gnanapragasam JP, et al.: Quality of life after repair of tetralogy of Fallot. Cardiol Young 2002, 12:549-553.
53. Culbert EL, Ashburn DA, Cullen-Dean G, et al.: Quality of life of children after repair of transposition of the great arteries. Circulation 2003, 108:857-862.
54. Sarubbi B, Pacileo G, Pisacane C, et al.: Exercise capacity in young patients after total repair of tetralogy of Fallot. Pediatr Cardiol 2000, 21:211-215.
55. Fredriksen PM, Veldtman G, Hechter S, et al.: Aerobic capacity in adults with various congenital heart diseases. Am J Cardiol 2001, 87:310-314.
56. Therrien J, Siu SC, Harris L, et al.: Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 2001, 103:2489-2494.
57. Geva T, Sandweiss BM, Gauvreau K, et al.: Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol 2004, 43:1068-1074. The authors describe the correlation between MRI assessment of right ventricular function and exercise capacity, and promote the use of MRI to aid in decision making regarding pulmonary valve surgery in long-term survivors of tetralogy of Fallot repair.
58. Khairy P, Landzberg MJ, Gatzoulis MA, et al.: Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study. Circulation 2004, 109:1994-2000. Prediction of which survivors will have increased morbidity and mortality after repair of congenital heart disease is difficult. This comprehensive article reviews data from several large case series, and describes the diagnostic and predictive value of electrophysiologic testing in this population, which is becoming increasingly clear.